Chemo4METPANC: A Phase 2 study with combination CHEmotherapy (Gemcitabine and Nab-Paclitaxel), cheMOkine (C-X-C) motif receptor 4 inhibitor (Motixafortide), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naive PANCreas adenocarcinoma
Chemo4METPANC: Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Motixafortide, and Cemiplimab in Pancreas Adenocarcinoma
Sponsor: Bioline and Regeneron
Enrolling: Male and Female Patients
IRB Number: AAAS9513
U.S. Govt. ID: NCT04543071
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if a combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for treatment of your type of cancer. Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer. Motixafortide has not been tested with the specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which you will receive and is being tested in this clinical trial.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have confirmed pancreatic cancer that has spread to other parts of your body (is metastatic)? Yes No
Are you willing to use birth control while on this study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162